These findings suggest that monitoring both diet and the blood level of inflammatory markers (including C-reactive protein, Interleukin-6, and the granulocyte-to-lymphocyte ratio) should be considered in a breast cancer reduction strategy, involving screening programs in the early diagnosis of cancer. This evidence concerns the gene CRP and breast carcinoma.